menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

Eli Lilly is buying a rare blood cancer biotech for up to $1.5 billion

5 0
yesterday

Get Quartz in your inbox

Free daily briefing on global business news.

Eli Lilly is buying a rare blood cancer biotech for up to $1.5 billion

The deal covers Calytrix's preclinical antibody for essential thrombocythemia and myelofibrosis, with milestone payments included

jetcityimage / Getty Images

Eli Lilly $LLY agreed to acquire Calytrix Bio, a privately held developer of therapies for myeloproliferative neoplasms, for up to $1.5 billion in cash, the company said on Monday.

Under the definitive agreement, Calytrix shareholders could receive up to $1.5 billion, made up of an upfront payment and further payments that depend on clinical and regulatory milestones being met, the company........

© Quartz